pdufa.bio
CalendarDecisionsReadoutsPatents
Drug IndexStocksScreenerConferencesAdvisory Committees
StudiesRun-up by YearLearnGlossaryMethodologyAPIAccount
Pro
Home › PDUFA Calendar › PRAX

PRAX PDUFA Date: Relutrigine (PRAX-562)

Updated ·next FDA decision on the calendar
FDA decision (PDUFA) target 2026-09-27 · Praxis Precision Medicines Inc. · Developmental epileptic encephalopathies (DEEs)
More CNS & Neurology FDA decisions →All September 2026 PDUFA dates →

The story

Relutrigine (PRAX-562) is under FDA review to treat Developmental epileptic encephalopathies (DEEs). Balance sheet: about 33 months of cash, runway into 2028 (company-guided).
Full PDUFA calendar ->Every upcoming FDA decision date, by monthNRXP . 2026-07-29Same area: Neurology . KETAFREELNTH-florquinitau . 2026-08-13Same area: Neurology . Florquinitau (MK-6240)TLX . 2026-09-11Same month decision . TLX101-Px
Plain-English summary compiled by pdufa.bio from public FDA, SEC and company sources. Informational only - not investment advice.

PRAX run-up into the PDUFA (last ~120 days)

$357.13$240.66
Price path to 2026-06-19. Green = local high, red = low/sell-off. Historical price action, not a forecast.

Key facts

FDA PDUFA target date2026-09-27
Drug / candidateRelutrigine (PRAX-562)
IndicationDevelopmental epileptic encephalopathies (DEEs)
CompanyPraxis Precision Medicines Inc.
Market-cap tierMid
Cohort decision-day move (history)±2% median
ClinicalTrials.govNCT05818553 · active

New to FDA decisions? Read what a PDUFA date is and how often the FDA approves drugs.

See the full 2026 PDUFA calendar →

FAQ

When is the PRAX PDUFA date?
The FDA PDUFA target date for PRAX (Praxis Precision Medicines Inc.) is 2026-09-27 for Relutrigine (PRAX-562). Dates are company/FDA-sourced and can slip. Verify against primary filings.
What is PRAX's drug Relutrigine (PRAX-562)?
Relutrigine (PRAX-562) is Praxis Precision Medicines Inc.'s candidate under FDA review for Developmental epileptic encephalopathies (DEEs).
What typically happens to a mid-cap stock into a PDUFA date?
Historically, mid-cap names had a median decision-day move around ±2% (763-PDUFA cohort, 2024-26). This is historical context by market-cap tier, not a prediction for this drug.
Decision-day move · mid-cap cohortn=222 · median -0.0% · 49% up
under -30%: 5 of 222 (2%)<-30-30 to -15%: 6 of 222 (3%)-15 to -7%: 7 of 222 (3%)-7 to -3%: 21 of 222 (9%)-3 to +3%: 134 of 222 (60%)±3+3 to +7%: 34 of 222 (15%)+7 to +15%: 9 of 222 (4%)+15 to +30%: 1 of 222 (0%)over +30%: 5 of 222 (2%)>+30
Distribution of next-day % moves after the FDA decision for mid-cap PDUFAs (2020–26). Red = down, green = up, blue = flat (±3%). Historical dispersion, not a forecast.